Akebia Therapeutics (AKBA) Asset Writedowns and Impairment (2019 - 2026)

Akebia Therapeutics (AKBA) has 8 years of Asset Writedowns and Impairment data on file, last reported at $3.2 million in Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 1873.01% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 2203.42% increase from a year earlier, with the FY2024 full-year figure at $294000.0, changed N/A from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $3.2 million, up from -$645000.0 in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for AKBA reached as high as $5.3 million in Q1 2022 and fell as low as -$9.6 million in Q4 2022.
• Historically, Asset Writedowns and Impairment has averaged $245562.5 across 5 years, with a median of $500000.0 in 2024.
• Across the five-year window, Asset Writedowns and Impairment sank 93.68% in 2023 and jumped 1873.01% in 2026, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at -$9.6 million in 2022, then soared by 86.17% to -$1.3 million in 2023, then tumbled by 58.93% to -$2.1 million in 2024, then surged by 69.42% to -$645000.0 in 2025, then jumped by 598.6% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $3.2 million in Q1 2026, -$645000.0 in Q4 2025, and $500000.0 in Q3 2025.